Articles tagged with Liver
A ketogenic diet reduced liver fat content and improved insulin resistance in overweight participants. The diet also increased hydrolysis of triglycerides and promoted ketogenesis, suggesting a possible mechanism for reversing nonalcoholic fatty liver disease.
A new study from the University of California, Davis found that ibuprofen causes significant changes in liver enzymes in laboratory mice. The research highlights marked differences in how males and females metabolize the drug, with potential implications for human health.
Researchers found that intermittent fasting affects liver enzymes and fatty acid metabolism in mice, revealing a surprising role played by the HNF4-alpha protein. This knowledge can help develop new interventions for cancer, cardiovascular, and diabetes diseases.
A new technology has been used to investigate the cellular processes involved in liver fibrosis development, revealing key genes and cell types that correlate with fibrogenesis. The findings have potential applications for diagnostic tools and therapies.
Research reveals glucose acts as a molecular switch regulating SIRT1's function, impacting gene expression and metabolic flexibility. Glucose modification affects organismal health, with both over-activation and under-activation linked to diseases.
Researchers found that liver fibrosis is tied to a specific type of heart failure, known as preserved ejection fraction heart failure (HFpEF), which affects people with and without HIV and hepatitis C. The study suggests that preventing liver fibrosis may be crucial in reducing the risk of HFpEF.
Yale scientists have discovered the molecular mechanisms that trigger metabolic imbalance between glucose production and energy utilization in the liver. They found that a protein called INSP3R1 regulates both gluconeogenesis and fat oxidation in response to glucagon, providing new insights into glucagon biology.
The study reveals a significant increase in survival rates after liver transplantation in the UK, with improvements seen in both short-time and long-term outcomes. The advancements are attributed to better surgical techniques and immunosuppression strategies.
A novel cause of fatty liver disease has been discovered in lean individuals undergoing immune checkpoint blockade therapy. Researchers report a case of a woman who experienced severe inflammation of her subcutaneous fat and developed nonalcoholic fatty liver disease after treatment with the PD-1 inhibitor Nivolumab.
A recent study published in Drug Metabolism and Disposition found that mice with drug-induced liver damage can safely take medications for diabetes, hypertension, and depression at lower doses. This breakthrough suggests that people with damaged livers may be able to continue taking life-saving medications while healing.
Researchers created a map of molecules in mouse organs, revealing that microbes control bile acid structure. This modification changes how cells communicate and genes are expressed, potentially affecting disease development. Novel microbial-modified bile acids were found in up to 25% of human samples.
Researchers have discovered a molecular pathway that, when silenced, restores immune cells' normal function in people with fatty liver disease. Silencing a microRNA molecule called miR144 increases the endogenous antioxidant response, suggesting a promising therapeutic strategy for treating non-alcoholic steatohepatitis.
A new website, transplantcentersearch.org, allows patients to compare transplant centers for kidney, liver, heart and lung transplants. The tool uses data from the Scientific Registry of Transplant Recipients to match factors important to each individual.
Research finds that persistent NRF2 activation may contribute to enlarged liver and fatty liver diseases, affecting over 200 million worldwide. AKT inhibitors show promise in treating hepatomegaly.
A protein called interleukin 6 (IL-6) plays a significant role in the spread of colorectal cancer to other parts of the body, particularly the liver. Suppressing IL-6 expression can enhance anti-tumor immune functions and improve patient survival.
Researchers at UCLA have identified a method to track the treatment of intestinal failure-associated liver disease (IFALD) in children by measuring the levels of micro-RNA 122. This non-invasive marker may be used to diagnose and monitor the disease without biopsies.
Scientists at UNIGE discovered a protein, S100A11, that promotes inflammation and build-up of fibrous tissue in the liver, increasing cancer severity. The presence of S100A11 in blood may enable early detection through simple blood sampling, paving the way for targeted therapies.
Researchers found that green tea extract and exercise reduced fatty liver deposits by 75% in mice fed a high-fat diet, suggesting a potential health strategy for people. The study also showed increased gene expression related to energy metabolism in mice treated with both green tea extract and exercise.
The new guidelines offer 29 evidence-based recommendations for managing adult acute and acute-on-chronic liver failure in the ICU, covering cardiovascular, hematologic, pulmonary, renal, and endocrine considerations. The guidelines also highlight areas needing further research to inform clinical practice.
A recent study published in the journal AIDS found that vitamin E improves liver function and reduces fat in patients with nonalcoholic steatohepatitis (NASH) and HIV. The treatment was well-tolerated and showed more significant improvements than reported in the general population.
A hybrid approach combining gene therapy and gene editing successfully treated an experimental model of a rare genetic disease, significantly enhancing survival. The findings could offer hope for children and adults with various inborn errors of metabolism.
A multi-center study has identified a research-based ultrasound screening method that can predict which children with cystic fibrosis are at higher risk for advanced liver disease. The test shows promise in identifying patients who could benefit from targeted therapies to prevent the development of this life-threatening condition.
Researchers developed a CRISPR gene-editing technique that prevented genetic liver disease in mice by introducing a 'minigene' that expresses the enzyme ornithine transcarbamylase. The approach showed promise for treating rare metabolic disorders and other hereditary diseases.
Researchers have discovered high levels of PFAS chemicals in the blood of Cape Fear River striped bass, which are associated with altered immune and liver functions. The study found elevated concentrations of PFOS and Nafion byproduct 2, particularly in smaller or younger fish, highlighting the unique properties of these chemicals.
University of California San Diego School of Medicine researchers identify a molecular pathway that allows nonalcoholic steatohepatitis (NASH) to progress into liver cell death. They found that suppressing AMPK and increasing caspase-6 activity can stop progression from fatty liver to NASH and subsequent liver cell death.
Researchers have discovered that indole, a natural compound found in gut bacteria and cruciferous vegetables, can reduce inflammation and fatty deposits in the liver. This study provides hope for new treatments and preventive measures for non-alcoholic fatty liver disease (NAFLD).
A Cedars-Sinai team will investigate the interplay between dietary fat and fatty liver disease to understand how cancer spreads to the liver and find ways to block it. The study aims to identify key mechanisms that allow cancer to spread to the liver and develop potential treatments.
A team of Yale researchers has discovered a way to reverse type-2 diabetes and liver fibrosis in mice, highlighting the potential for targeting TET3 protein. The studies, published in Cell Reports and Nature Communications, also suggest that TET3 plays a role in fibrosis development and may be a key target for treatment.
Researchers found improved survival times of 13.6 months and 17.8 months for uveal melanoma patients with liver metastasis treated with new therapies, compared to 5.3 months in earlier years. The shift from systemic chemotherapy to targeted liver treatments has led to significant benefits.
Researchers at UC San Diego School of Medicine identified genetic switches that determine whether or not liver cells produce collagen, leading to a potential therapeutic target for liver fibrosis. By manipulating these transcription factors, liver fibrosis progression can be addressed.
New study finds liver mesenchymal stromal cells have immunoregulatory qualities making them more effective than similar cells derived from bone marrow and fat tissue. The discovery could lead to better treatment options for diseases like organ rejection, inflammatory bowel disease, and autoimmune disorders.
Researchers at University College London discovered that T cells in the liver can 'recycle' material through autophagy, a process enabled by the cytokine IL-15. This breakthrough could lead to more effective immunotherapies for cancer and chronic viral infections.
Scientists discovered that magnetic nanoparticles can target and treat liver fibrosis by delivering drugs to the affected tissue, reducing inflammation and improving liver function. This new approach offers a potential solution for treating this fatal illness with improved patient outcomes.
Researchers found that estrogen regulates accumulation of immune cells in the liver, promoting tumor growth and immune suppression. The study suggests exploring sex hormones in female cancer patients and using anti-estrogen drugs to improve immunotherapy outcomes.
A UK study found that over 20% of young adults have fatty liver disease, with those who are overweight or obese at greatest risk. The research highlights the need for improved liver health awareness and management among this age group.
Researchers develop machine that repairs injured human livers and keeps them alive for a week outside the body. The technology increases the number of available organs for transplantation, saving lives of patients with severe liver diseases or cancer.
SIRT6, a longevity protein, plays a crucial role in burning and regulating liver fat metabolism. By activating PPAR-alpha, it promotes fat burning and protects against fatty liver and obesity-related damage.
Cynthia Ju, a UTHealth scientist, has been awarded $3.6 million in NIH grants to investigate molecules linked to liver injuries. Her research aims to identify potential therapeutic targets to enhance or block the activity of these molecules.
Research led by UMass Amherst scientist Alexander Suvorov identified the mechanism responsible for flame retardant's effect: an altered liver epigenome. Perinatal exposure permanently changed liver metabolism in rats, potentially applicable to humans.
Researchers propose using transient elastography as a screening method for detecting liver fibrosis in primary care. The study shows that this approach is highly cost-effective and can improve patient outcomes, with a 12% probability of cost saving.
Lylex Pharmaceuticals is developing compounds targeting key enzymes responsible for organ damage, inflammation and rejection after transplant. The lead compound has shown high potency while minimizing toxic effects.
A new study found that an existing antiviral treatment is effective against both the hepatitis C virus and potentially fatal complications such as reduced liver functioning and cirrhosis. The treatment also improves cognitive function, with patients experiencing improved reaction times.
A global clinical trial has demonstrated the safety and effectiveness of an oral medication to treat nonalcoholic steatohepatitis (NASH), a chronic liver disease. The treatment, obeticholic acid, showed the ability to reverse liver scarring in patients most at risk for irreversible liver damage.
Scientists have developed a 3D model of the human liver to improve diagnosis of non-alcoholic fatty liver disease. The model reveals new critical tissue alterations, providing insights into pathophysiology and contributing to high-definition medical diagnosis.
A study by Adrien Guillot et al. found that knockout of the ALDH-2 enzyme in mice reduces excessive but not moderate alcohol seeking activity. Targeting this enzyme specifically in the liver may prevent heavy drinking without affecting moderate consumption.
Researchers found that type I interferon disrupts the urea cycle in liver cells, leading to altered serum metabolite concentrations and reduced liver pathology. This regulation affects antiviral immunity and reduces liver damage.
Scientists at Scripps Research Institute have discovered a little-known protein that plays a crucial role in managing glucose and insulin levels in the body. The protein, PGRMC2, acts as a chaperone for heme, a molecule essential for cellular processes, and its absence is linked to obesity and metabolic diseases.
A recent study by researchers at the Medical University of South Carolina found that ammonia levels do not predict the severity of disease or guide clinical management of hepatic encephalopathy in cirrhotic patients. Cirrhotic patients with HE symptoms receive the same lactulose treatment regimen regardless of their blood ammonia levels.
Researchers successfully applied phage therapy to mice with alcohol-related liver disease, eradicating the disease by targeting destructive gut bacteria. Nearly 90% of patients with cytolysin-positive alcoholic hepatitis died within 180 days, but phage therapy showed promise in treating the condition.
Researchers at University of California San Diego School of Medicine successfully applied phage therapy in mice for a condition not considered a classic bacterial infection: alcoholic liver disease. Phages target the cytolysin toxin produced by Enterococcus faecalis, reducing bacteria and alleviating liver damage.
Research suggests that impaired liver function during pregnancy can lead to altered gut bacteria composition in children, increasing the risk of obesity. Maintaining a healthy diet and targeting gut microbiome composition with pre-biotics or pro-biotics may help prevent childhood obesity.
A high-caloric diet alters the time-of-day dependent metabolic cycle in mice, suggesting lean and obese patients may respond differently to steroid therapy. The study also highlights the biological function of daily hormone secretion cycles and their impact on sugar and fat storage or release by the liver.
Researchers found budesonide reduced serious side effects like new onset diabetes and bone loss in liver transplant patients, while maintaining comparable organ rejection rates to prednisone. The study involved 20 patients and showed lower infection rates and improved blood sugar control.
Researchers found that artificial intelligence can detect subtle language changes in patients with failing livers, suggesting a potential diagnostic tool for early identification of cognitive issues. Following a liver transplant, patients returned to normal or near-normal language patterns.
A new study reveals that the Liver-Chip model can recreate species-specific toxicity responses to known tool and drug compounds, improving safety predictions in humans. The research demonstrates how this platform could help ensure that safe and effective therapeutics are identified sooner.
Researchers have identified a molecule called TET1 that enables adult liver cells to regenerate. The discovery provides a potential target for drugs to treat chronic liver diseases, where regeneration is impaired.
Researchers at Seattle Children's describe how malaria Plasmodium parasites prepare a blueprint of proteins needed to infect the liver while waiting in mosquito salivary glands. This knowledge may lead to new strategies to block transmission and ultimately eradicate malaria.
A clinical trial will investigate the use of S-adenosylmethionine (SAMe) to improve liver function and mortality in patients with alcoholic cirrhosis. The study, led by IU School of Medicine researcher Suthat Liangpunsakul, aims to provide new avenues for treating this condition.
Researchers at Georgia State University have developed a protein-based contrast agent that can detect early-stage liver diseases, including liver fibrosis, with high accuracy and sensitivity. The new method uses a lower dosage of contrast metal gadolinium, reducing the risk of metal toxicity and enabling earlier diagnosis and treatment.
Researchers at Charité - Universitätsmedizin Berlin developed a new diagnostic technique using tomoelastography to visualize liver tumor mechanical properties. The study found that hepatic malignancies contain tissues with both stiff and fluid properties, contrary to previous assumptions.